Leads Biolabs-B (09887.HK): Varisin Combination Therapy for First-Line Treatment of Gastric Cancer Phase II Study Enters Expansion Stage

Zhito Finance APP News, LBL-B(09887.HK) announced that the Phase II clinical study of its self-developed Vilixin (opamtisumumab, anti-PD-L1/4-1BB bispecific antibody) in combination therapy for first-line treatment of locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma has completed the safety lead-in phase evaluation, demonstrating positive efficacy signals and supporting its advancement to the expansion phase. To date, the clinical development of Vilixin in the gastrointestinal tumor field now covers five major tumor types: biliary tract cancer (BTC), hepatocellular carcinoma (HCC), esophageal squamous cell carcinoma (ESCC), colorectal cancer (CRC), and gastric cancer (GC), of which four studies have advanced to the expansion phase.